Your browser is no longer supported. Please, upgrade your browser.
CLVS Clovis Oncology, Inc. daily Stock Chart
Clovis Oncology, Inc.
Index- P/E- EPS (ttm)-8.23 Insider Own0.50% Shs Outstand46.82M Perf Week12.22%
Market Cap2.55B Forward P/E- EPS next Y-2.77 Insider Trans-3.70% Shs Float43.06M Perf Month0.09%
Income-324.20M PEG- EPS next Q-1.28 Inst Own84.30% Short Float19.53% Perf Quarter-13.57%
Sales7.10M P/S359.00 EPS this Y7.40% Inst Trans17.75% Short Ratio4.63 Perf Half Y49.97%
Book/sh3.96 P/B13.75 EPS next Y44.00% ROA-73.40% Target Price68.64 Perf Year275.45%
Cash/sh8.73 P/C6.24 EPS next 5Y31.90% ROE-380.90% 52W Range11.57 - 74.94 Perf YTD22.56%
Dividend- P/FCF- EPS past 5Y-29.60% ROI- 52W High-27.36% Beta1.78
Dividend %- Quick Ratio7.20 Sales past 5Y- Gross Margin82.70% 52W Low370.53% ATR2.84
Employees278 Current Ratio7.30 Sales Q/Q- Oper. Margin- RSI (14)50.76 Volatility5.93% 5.65%
OptionableYes Debt/Eq1.62 EPS Q/Q38.90% Profit Margin- Rel Volume0.76 Prev Close52.24
ShortableYes LT Debt/Eq1.62 EarningsMay 03 AMC Payout- Avg Volume1.82M Price54.44
Recom2.30 SMA203.74% SMA50-6.53% SMA20022.78% Volume1,383,763 Change4.21%
May-17-17Upgrade JP Morgan Neutral → Overweight
Feb-03-17Downgrade Chardan Capital Markets Neutral → Sell $36
Jan-27-17Initiated BofA/Merrill Buy $74
Jan-26-17Upgrade Piper Jaffray Neutral → Overweight
Jan-23-17Reiterated Stifel Buy $52 → $86
Jan-13-17Initiated Morgan Stanley Overweight
Dec-21-16Reiterated WallachBeth Hold $22 → $49
Dec-20-16Upgrade Chardan Capital Markets Sell → Neutral $15 → $36
Oct-25-16Initiated Chardan Capital Markets Sell $15
Sep-23-16Reiterated SunTrust Buy $38 → $50
Sep-21-16Upgrade Credit Suisse Neutral → Outperform
Sep-21-16Reiterated Stifel Buy $30 → $45
Aug-24-16Reiterated Mizuho Neutral $15 → $23
Aug-05-16Initiated SunTrust Buy
May-09-16Reiterated WallachBeth Hold $30 → $22
Apr-13-16Reiterated Mizuho Neutral $21 → $15
Apr-13-16Downgrade JP Morgan Overweight → Neutral
Apr-13-16Downgrade Credit Suisse Outperform → Neutral
Apr-04-16Resumed Piper Jaffray Neutral
Feb-29-16Reiterated Mizuho Neutral $23 → $21
May-22-17 08:58AM  Clovis' (CLVS) PARP Inhibtor Shows Promise, Risks Remain Zacks
May-17-17 05:05PM  Did AstraZeneca Rival Just Launch A Potential Blockbuster Drug? Investor's Business Daily
May-12-17 05:21PM  Edited Transcript of CLVS earnings conference call or presentation 3-May-17 8:30pm GMT Thomson Reuters StreetEvents
May-07-17 08:20PM  Edited Transcript of CLVS earnings conference call or presentation 3-May-17 8:30pm GMT Thomson Reuters StreetEvents
May-04-17 04:48PM  How Clovis Might Still Quash AstraZeneca, Tesaro In Cancer Investor's Business Daily
01:29PM  Biotech Stock Mailbag: Why Clovis Oncology Is Trading Lower on Rubraca Study Update
10:27AM  Clovis (CLVS) Q1 Loss Narrows, Rubraca Off to a Good Start Zacks
May-03-17 05:44PM  Clovis reports 1Q loss Associated Press
04:05PM  Clovis Oncology Announces First Quarter 2017 Operating Results Business Wire
Apr-27-17 07:05AM  Myriad Genetics and Clovis Oncology Sign Agreement for Use of FDA-Approved BRACAnalysis CDx® Test to Identify Patients with Germline BRCA Mutations for Rubraca® (rucaparib) Treatment GlobeNewswire
Apr-25-17 03:43PM  Tesaro Inc Bulls Need a Reality Check Motley Fool
Apr-21-17 07:21AM  Tesaro's Path to a Billion-Dollar Blockbuster Begins With Pricing Motley Fool
06:52AM  Tesaros Zejula Flops as H&S Pattern Emerges Investopedia
Apr-20-17 04:22PM  Tesaro Dives On 'Sticker Shock' For $177,000 Drug Investor's Business Daily
01:21PM  AbbVie's PARP Inhibitor Comes Up Empty Motley Fool
08:00AM  Clovis Oncology to Announce First Quarter 2017 Financial Results and Host Webcast Conference Call on May 3 Business Wire
Apr-17-17 08:42AM  3 Cancer Drug Stocks That Could Make You Rich Motley Fool
Apr-10-17 09:30AM  Today's Research Reports on Biotech Stocks to Watch: Nektar Therapeutics and Clovis Oncology Accesswire
Apr-07-17 04:53PM  Why Clovis Oncology's Stock Edged Higher in March Motley Fool
Mar-31-17 08:33AM  Clovis Oncology, Inc. breached its 50 day moving average in a Bearish Manner : CLVS-US : March 31, 2017 Capital Cube
08:33AM  Clovis Oncology, Inc. breached its 50 day moving average in a Bearish Manner : CLVS-US : March 31, 2017
Mar-29-17 11:41AM  AstraZeneca's (AZN) Lynparza NDA Accepted for Review by FDA Zacks
11:41AM  AstraZeneca's (AZN) Lynparza NDA Accepted for Review by FDA at Investopedia
12:10AM  [$$] Overheard The Wall Street Journal
12:10AM  [$$] Overheard at The Wall Street Journal
Mar-28-17 06:03PM  Tesaro Wins FDA Approval for Ovarian Cancer Drug Zejula Investopedia
06:03PM  Tesaro Wins FDA Approval for Ovarian Cancer Drug Zejula at Investopedia
04:30PM  Clovis Oncology Announces Data Presentations at AACR Annual Meeting 2017 Business Wire
04:19PM  Why Clovis' Advantage Might Squash Tesaro In Ovarian Cancer Investor's Business Daily
04:19PM  Why Clovis' Advantage Might Squash Tesaro In Ovarian Cancer
09:23AM  Biotech M&A Trade Hits a Snag The Wall Street Journal
09:23AM  Biotech M&A Trade Hits a Snag at The Wall Street Journal
03:30AM  Why Is Clovis (CLVS) Up 18.8% Since the Last Earnings Report? Zacks
Mar-27-17 08:42PM  Tesaro wins FDA approval for potential blockbuster cancer drug at
04:33PM  Tesaro Creeps Up On Rivals With Cancer Drug OK, But Merger Unlikely Investor's Business Daily
04:33PM  Tesaro Creeps Up On Rivals With Cancer Drug OK, But Merger Unlikely
04:07PM  Tesaro Secures Early and Broad Approval for PARP Inhibitor in Ovarian Cancer
Mar-24-17 06:35PM  SHAREHOLDER ALERT: Law Office of Brodsky & Smith, LLC Announces Investigation of the Board of Directors of Clovis Oncology, Inc. - CLVS Accesswire
Mar-22-17 08:02AM  3 Stocks at 52-Week Highs Still Worth Buying at Motley Fool
Mar-21-17 03:02PM  Billionaires' Best Healthcare Stock Picks of 2017 (So Far) at Motley Fool -7.78%
Mar-20-17 03:37PM  Look for Clovis Oncology to Resume Its Advance
Mar-17-17 09:33AM  5 Biotech Companies To Watch In 2017
07:30AM  5 Biotech Companies Set for Major Breakouts In 2017
Mar-16-17 02:49PM  AstraZeneca PLC (ADR) (AZN)s Lynparza Trial Results Positive In Competitive Threat To Clovis Oncology Inc (CLVS) And TESARO Inc (TSRO) at Insider Monkey
08:52AM  3 tech and biotech stocks with momentum at MarketWatch
Mar-15-17 04:15PM  Tesaro Sell-Off On AstraZeneca Ovarian Cancer Trial Overdone: Analyst +7.44%
01:54PM  Heres What Just Happened With AstraZeneca PLC (ADR) (AZN), TESARO Inc (TSRO) And Clovis Oncology Inc (CLVS) at Insider Monkey
01:19PM  AstraZeneca Ovarian Cancer Drug Succeeds in Trial at Investopedia
08:32AM  Lynparza Vs. Niraparib
08:08AM  Clovis Shares Reiterated As A Sell Following 10% Rally
07:46AM  Goldman Sachs Raises Clovis Oncology Price Target to $75
07:30AM  6 Stocks Trending Up With Major Volume
Mar-14-17 04:17PM  Tesaro Trips On AstraZeneca's Ovarian Cancer Trial While Clovis Climbs +10.48%
04:09PM  Why Tesaro is Tanking at
03:43PM  AstraZeneca Takes PARP Inhibitor Fight to Rival Tesaro with Strong Ovarian Cancer Study Results
02:30PM  AstraZeneca ovarian cancer drug slows disease markedly in study
Mar-12-17 10:30AM  Clovis Oncology Presents New Data from Phase 2 Studies of Rucaparib in Advanced Ovarian Cancer at 2017 SGO Annual Meeting on Womens Cancer Business Wire
Mar-01-17 04:22PM  Tesaro Eyes Immuno-Oncology As AstraZeneca, Clovis Loom: Analyst
01:04PM  CLOVIS ONCOLOGY, INC. Financials
Feb-24-17 10:20AM  Merrill Lynch Raises Price Targets on 3 Red-Hot Tech and Biotech Stocks
Feb-23-17 05:19PM  CLOVIS ONCOLOGY, INC. Files SEC form 10-K, Annual Report -5.69%
10:48AM  Clovis Oncology 4Q Loss Below Street Estimates at Investopedia
09:39AM  [2/23] This Weeks Earnings Revisions Movers
08:59AM  Clovis (CLVS) Q4 Loss Wider than Expected; Focus on Rubraca
Feb-22-17 11:58PM  Edited Transcript of CLVS earnings conference call or presentation 22-Feb-17 9:30pm GMT
05:06PM  Clovis reports 4Q loss
04:30PM  Clovis Oncology Inc Earnings Call scheduled for 4:30 pm ET today
04:14PM  CLOVIS ONCOLOGY, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exh
04:05PM  Clovis Oncology Announces 2016 Operating Results Business Wire
Feb-18-17 08:41PM  Johnson & Weaver, LLP Announces Investigations of Clovis Oncology, Inc., USANA Health Sciences, Inc., Anthera Pharmaceuticals, Inc., and PixarBio Corporation PR Newswire
Feb-17-17 04:31PM  AstraZeneca Could Give Pfizer, Tesaro Leg Up In Breast Cancer: Leerink +7.22%
01:38PM  Clovis, Tesaro Soar on Astrazeneca Phase Three News
Feb-14-17 12:40PM  Update in Lawsuit for Investors in shares of Clovis Oncology Inc (NASDAQ:CLVS) announced by Shareholders Foundation GlobeNewswire
Feb-13-17 01:00AM  Morgan Stanley, Twitter, Tesaro: Doug Kass' Views
Feb-09-17 06:05PM  Clovis Oncology to Announce Fourth Quarter/Year-End 2016 Financial Results and Host Webcast Conference Call on February 22 Business Wire
Feb-08-17 04:53PM  3 Scorching Hot Biotech Stocks -- Are They Buys? at Motley Fool +5.68%
12:49PM  Biotech Tesaro Climbs on Takeout Reports
Feb-03-17 06:52AM  Clovis Oncology downgraded by Chardan Capital Markets
Feb-01-17 08:31AM  CLOVIS ONCOLOGY, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement
08:30AM  Clovis Oncology and Strata Oncology Announce Collaboration to Accelerate Enrollment in Rucaparib Prostate Cancer Development Program Business Wire
Jan-31-17 12:59PM  Clovis Oncology Inc (CLVS)s Ovarian Cancer Drug Faces Stiff Competition From AstraZeneca PLC (ADR) (AZN), TESARO Inc (TSRO) at Insider Monkey
Jan-30-17 04:12PM  Tesaro, AstraZeneca Could Shrink Clovis' Ovarian Cancer Drug Pool
07:27AM  3 Mid-Cap Biotech Stocks to Buy in February at Motley Fool
Jan-27-17 08:40AM  Clovis Oncology (CLVS) in Focus: Stock Moves 5.6% Higher
Jan-22-17 01:27PM  3 Biotechs Likely to Be Acquired in 2017 at Motley Fool
Jan-17-17 08:05AM  What's Behind Clovis' (CLVS) One-Year Rally of 146.3%?
Jan-10-17 09:30AM  The Zacks Analyst Blog Highlights: Clovis Oncology, Pfizer, Roche's, Sanofi and Regeneron Pharmaceuticals
Jan-09-17 10:48AM  CLOVIS ONCOLOGY, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Financial Stateme +10.49%
08:00AM  Clovis Oncology to Present at the 35th Annual J.P. Morgan Healthcare Conference Business Wire
Jan-04-17 09:40PM  Clovis Oncology Announces Exercise in Full of Underwriters Option to Purchase Additional Shares of Common Stock Business Wire
09:43AM  Clovis Declares Pricing of Upsized Offering of Common Stock
Jan-03-17 06:45PM  Clovis Oncology Announces Upsizing and Pricing of Public Offering of Common Stock Business Wire
11:10AM  Tuesdays Biggest Biotech and Pharma Moves
06:45AM  Clovis Oncology Announces Proposed Offering of Common Stock Business Wire
06:35AM  17 Thoughts on Biotech Stocks to Kick Off 2017
Dec-30-16 04:22PM  Biotech Stocks: What to Watch in 2017 at Motley Fool
Dec-28-16 08:35AM  Eight Milestones Of 2016 In The War On Cancer at Forbes
Dec-27-16 02:32PM  Expect Availability Of Biogen's Newly Approved Spinraza In Just One Week
Dec-23-16 01:32PM  Growth-stock speculators need to tap the brakes here at MarketWatch
Dec-22-16 09:36AM  2016's Worst Clinical Failures at Motley Fool
Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. Its commercial product includes Rubraca (rucaparib) tablet, an oral and small molecule poly ADP-ribose polymerase inhibitor as monotherapy for the treatment of patients with deleterious breast cancer mutation associated advanced ovarian cancer, who have been treated with two or more chemotherapies, and selected for therapy by an FDA-approved companion diagnostic for Rubraca. The company is also involved in the ARIEL3 and ARIEL4 confirmatory trials of rucaparib as a potential maintenance therapy and treatment for ovarian cancer; trial of rucaparib in prostate indications (TRITON) 2, a Phase 2 single-arm study in men with metastatic castrate-resistant prostate cancer; and TRITON3, a Phase 3 comparative study in men with mCRPC enrolling BRCA mutant and ATM, as well as engages in the various clinical studies for other indications. It distributes its product primarily through specialty distributors and pharmacy providers to patients and health care providers. The company has license agreements with Pfizer Inc., AstraZeneca UK Limited, Advenchen Laboratories LLC, and Celgene Corporation; and collaboration and license agreement with Les Laboratoires Servier. Clovis Oncology, Inc. was founded in 2009 and is headquartered in Boulder, Colorado.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
IVERS-READ GILLIAN CSee RemarksMay 15Sale47.393,000142,170203,583May 15 06:24 PM
IVERS-READ GILLIAN CSee RemarksApr 17Sale56.023,000168,060206,583Apr 17 06:04 PM
IVERS-READ GILLIAN CSee RemarksMar 15Sale66.993,000200,970209,583Mar 15 05:15 PM